Longacef suspensión

Longacef suspensión is an oral antibiotic formulation containing cefixime, a third-generation cephalosporin. Developed and marketed by Megat Pharmaceutical in Ecuador, it is provided as a powder for oral suspension (100 mg/5 ml) primarily intended for pediatric use. Cefixime is a small molecule drug that exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) located in the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, leading to cell wall lysis and bacterial death. Longacef is indicated for the treatment of various bacterial infections, including acute bronchitis, pneumonia, otitis media, pharyngitis, tonsillitis, and uncomplicated urinary tract infections, and is noted for its stability against many beta-lactamase enzymes.

Brand names

Longacef suspensión

Other names

Longacefcefixime oral suspension